STAT Plus: Spring Bank scraps hepatitis R&D after patient dies in trial

Spring Bank Pharmaceuticals (SBPH) said Wednesday it was abandoning efforts to develop a drug to treat hepatitis B as a result of “unexpected serious adverse events,” including a patient’s death in a mid-stage clinical trial.

“We are deeply saddened by the death of a patient in our Catalyst 2 trial,” Martin Driscoll, president and chief executive of Spring Bank, said of the clinical trial testing an experimental drug called inarigivir soproxil.

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: Spring Bank scraps hepatitis R&D after patient dies in trial »